Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.72 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | STAT3 | P40763 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | TYK2 | P29597 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5466118 | 0.99 | ROCK2 (0.72) | ROCK2ROCK1KDM4EL3MBTL1LMNA | |
| SCHEMBL5451870 | 0.89 | ROCK2 (0.68) | ROCK2ROCK1KDM4EL3MBTL1LMNA | |
| SCHEMBL2793935 | 0.87 | ROCK2 (0.69) | ROCK2ROCK1KDM4EL3MBTL1LMNA | |
| SCHEMBL2790408 | 0.87 | ROCK2 (0.69) | ROCK2ROCK1KDM4EL3MBTL1LMNA | |
| SCHEMBL2795043 | 0.87 | ROCK2 (0.69) | ROCK2ROCK1KDM4EL3MBTL1LMNA | |
| SCHEMBL5473994 | 0.87 | ROCK2 (0.65) | ROCK2ROCK1KDM4EL3MBTL1LMNA | |
| SCHEMBL2792305 | 0.86 | ROCK2 (0.68) | ROCK2ROCK1KDM4EL3MBTL1LMNA | |
| SCHEMBL6557935 | 0.86 | ROCK2 (0.68) | ROCK2ROCK1KDM4EL3MBTL1LMNA | |
| Hydrochloric Acid SCHEMBL2794136 | 0.86 | ROCK2 (0.70) | ROCK2ROCK1KDM4EL3MBTL1LMNA | |
| Hydrochloric Acid SCHEMBL2789873 | 0.86 | ROCK2 (0.70) | ROCK2ROCK1KDM4EL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1715862-A1 | KINASE INHIBITORS | Devgen NV (BE) | 2006-11-02 | — | — | EP | claimed |
| WO-2005082367-A1 | KINASE INHIBITORS | DEVGEN NV (BE) | 2005-09-09 | — | — | WO | claimed |
| WO-2010049173-A1 | USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES | CENIX BIOSCIENCE GMBH (DE) | 2010-05-06 | — | — | WO | disclosed |
| US-20070191420-A1 | Kinase inhibitors | DEVGEN NV | 2007-08-16 | — | — | US | disclosed |
| US-20070191420-A1 | Kinase inhibitors | DEVGEN NV | 2007-08-16 | — | — | US | disclosed |
| EP-1391454-A1 | Substituted benzamide compounds with antihypertensive activity | Mitsubishi Pharma Corporation (JP) | 2004-02-25 | — | — | EP | disclosed |
| EP-1195372-A1 | N-heterocyclic substituted benzamide derivatives with antihypertensive activity | Mitsubishi Pharma Corporation (JP) | 2002-04-10 | — | — | EP | disclosed |
| US-6156766-A | Benzamide compounds and pharmaceutical use thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-12-05 | — | — | US | disclosed |
| US-5958944-A | TREATMENT OF CIRCULATORY DISEASES IN CORONARY, CEREBRAL, RENAL AND PERIPHERAL ARTERIES, AS A THERAPEUTIC AGENT FOR HYPERTENSION, ANGINA PECTORIS, AND RENAL AND PERIPHERAL CIRCULATION DISORDER, ANTIASTHMATIC AGENT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-28 | — | — | US | disclosed |
| EP-0757038-A1 | BENZAMIDE COMPOUND AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191420-A1 | Kinase inhibitors | ROCK1, ROCK2, MAP3K20 | ROCK2 2/4885ROCK1 1/4885KDM4E 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.